131 results about "Atrial natriuretic peptide" patented technology

A diagnostic tool is disclosed for accurately and rapidly diagnosing the condition of an ailing organ. Although applicable to numerous organ and organ systems, this application particularly illustrates the concept of conjunctive marker utilization as it relates to diagnosing and distinguishing congestive heart failure. The invention particularly relates to the conjunctive utilization of cardiac Troponin I (cTn-I) and natriuretic peptide, e.g. ANP, pro-ANP, BNP, pro-BNP and CNP as a retrospective tool for diagnosing the underlying mechanism of heart failure and as a prospective analytical device for monitoring disease progression and efficacy of therapeutic agents.

The present invention provides reagents and assays for the quantification of hBNP in biological fluid samples such as plasma or serum. Antibodies are provided which are monospecific to epitopes comprising the amino acid sequences 5-13, 1-10 and 15-25 of hBNP. These antibodies, and peptide fragments containing these sequences, can be employed in the assays of the invention, which may be carried out in a sandwich format or a competition format.

The present invention relates to the identification and use of polypeptides that bind to antibodies directed to a desired polypeptide of interest. Using natriuretic peptides and their precursors, and in particular BNP, as an example, the present invention describes a number of natriuretic peptides fragments produced in biological samples, most preferably blood-derived samples, that bind to antibodies directed to BNP. Because production of such fragments is an ongoing process that may be a function of, inter alia, the elapsed time between onset of an event triggering natriuretic peptide release into the tissues and the time the sample is obtained or analyzed; the elapsed time between sample acquisition and the time the sample is analyzed; the type of tissue sample at issue; the storage conditions; the quantity of proteolytic enzymes present; etc., such fragments may be used when both designing an assay for one or more natriuretic peptides, and when performing such an assay, in order to provide an accurate prognostic or diagnostic result.

The present invention discloses proteinaceous compounds that comprise at least a biologically active portion of a taipan natriuretic peptide (TNP) or a variant or derivative thereof. The invention also relates to the use of these compounds in methods for stimulating vasodilation, natriuresis, diuresis, renin-suppression, bactericidal activity, weight-loss or bone growth in a mammalian host. In specific embodiments, the compounds are useful in the treatment of congestive heart failure.

Human receptor selective atrial natriuretic factor variants containing various substitutions, especially G16R, show equal potency and binding affinity for the human A-receptor but have decreased affinity for the human clearance or C-receptor. These ANF variants have natriuretic, diuretic and vasorelaxant activity but have increased metabolic stability, making them suitable for treating congestive heart failure, acute kidney failure and renal hypertension.

The present invention describes compositions and methods designed to determine the presence or amount of biologically active natriuretic peptides, or their fragments, in a sample. The degradation of natriuretic peptides is an ongoing process that may be a function of, inter alia, the elapsed time between onset of an event triggering natriuretic peptide release into the tissues and the time the sample is obtained or analyzed; the quantity of proteolytic enzymes present; etc. This degradation can produce circulating amounts of natriuretic peptides having reduced or lost biological function. The present invention provides, inter alia, assays designed to accurately measure biologically active natriuretic peptides, and compositions to inhibit a previously unknown pathway for degradation of natriuretic peptides.

Natriuretic peptide fusion proteins comprising natriuretic peptides linked to antibody Fc domains, nucleic acid molecules encoding the fusion proteins disclosed herein, expression vectors expressing said fusion proteins, pharmaceutical compositions comprising said fusion proteins, and methods for their therapeutic use are disclosed.

The invention relates to a kit for detecting brain natriuretic peptide in blood serum and provides the kit for detecting brain natriuretic peptide by nano microsphere immunonephelometry, which has the characteristics of no need of dilution of a sample, simple operation, high precision, good repeatability and suitability for a clinically common used automatic biochemical analyzer, in order to solve technical problems. The invention adopts a technical scheme that the kit for detecting the brain natriuretic peptide by nano microsphere immunonephelometry comprises the following components: a, a reagent R1 which comprises buffer solution, a preservative, a stabilizing agent, an electrolyte, a surfactant, and the balance of water; b, a reagent R2 which comprises buffer solution, nano microspheres combined with brain natriuretic peptide antibodies and a preservative, wherein the diameter of the microspheres is 50 to 150 nm; and c, a reference calibration material which comprises buffer solution, a stabilizing agent, a preservative, a recombinant brain natriuretic peptide pure product which is added in a corresponding amount according to the required concentration of the BNP (brain natriuretic peptide) reference calibration material, and the balance of water.

An apparatus and method for transdermally delivering a natriuretic peptide comprising a delivery system having a microprojection member that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers. In one embodiment, the natriuretic peptide is contained in a biocompatible coating that is applied to the microprojection member. In a further embodiment, the delivery system includes a natriuretic peptide-containing hydrogel formulation. In an alternative embodiment, the natriuretic peptide is contained in both the coating and the hydrogel formulation. In yet another embodiment, the natriuretic peptide is contained in a solid state formulation.

Methods, compositions and devices are provided by the present invention for reducing activity of a natriuretic peptide receptor and other signals. Therapeutic treatments are provided by use of polynucleotides encoding a natriuretic peptide or by regulating the expression of natriuretic peptide receptor, such as NPRA and NPRC, or combinations of these therapies. Routes used for delivering polynucleotides encoding a natriuretic peptide, or, for example, siRNA that down regulates natriuretic peptide receptor include subcutaneous injection, oral gavage, transdermal and intranasal delivery routes. Compositions can include chitosan, chitosan derivatives, and chitosan derivative and a lipid. Transdermal delivery can use a transdermal cream. Intranasal delivery can use a dropper or an aspirator for delivery of a mist. Oral gavage delivers equivalent to oral delivery. Delivery permits cell and tissue specific targeting of gene therapies resulting in expression of a natriuretic peptide or down regulation of natriuretic peptide receptor. A variety of cancers, asthma and viral diseases can be treated therapeutically using the methods and compositions of the present invention.

Immunoassays and antibodies useful in conducting them for human and canine brain natriuretic peptide are described.

The present invention provides methods, compositions, and kits for the treatment of neurocutaneous syndromes, such as neurofibromatosis type I; disorders associated with overactivation of FGFR3, such as achondroplasia; bone or cartilage disorders; or vascular smooth muscle disorders; or for the elongation of bone. In some embodiments, the present invention provides polypeptides having an alkaline phosphatase peptide fused to an Fc domain of an immunoglobulin or a natriuretic peptide fused to an Fc domain of an immunoglobulin. Such polypeptides can be administered to subjects, e.g., subcutaneously, to treat a neurocutaneous syndrome, a disorder associated with overactivation of FGFR3, a bone or cartilage disorder, or a vascular smooth muscle disorder, or to elongate bone. The invention also features nucleic acid molecules encoding such polypeptides and the use of the nucleic acid molecules for treating neurocutaneous syndromes, disorders associated with overactivation of FGFR3, bone or cartilage disorders, or vascular smooth muscle disorders, or for elongating bone.

The present invention pertains to a method for treatment of allergic diseases by administering a natriuretic hormone peptide (NHP), or a nucleic acid sequence encoding NHP, to a patient in need thereof. In another aspect, the present invention concerns an expression vector comprising a nucleic acid sequence encoding NHP. In another aspect, the present invention concerns a host cell genetically modified with a nucleic acid sequence encoding NHP. In another aspect, the present invention concerns a pharmaceutical composition comprising NHP or a nucleic acid sequence encoding NHP and a pharmaceutically acceptable carrier. In another aspect, the present invention pertains to novel fragments of atrial natriuretic peptide (ANP) exhibiting bronchodilatory and anti-inflammatory activity, and isolated nucleic acid sequences encoding the fragments.

The present invention includes a method of utilizing four peptide hormones to inhibit the growth of cancer(s). A dramatic decrease in the number of human pancreatic adenocarcinoma cells (i.e., the type of cancer with the highest mortality, with patients only surviving four months) was observed responsive to treatment. The application of the invention would be to utilize one or more of these peptide hormones alone and / or in combination to treat cancer. The ability of these peptide hormones to decrease the number of adenocarcinoma cells has implications for adenocarcinomas at other sites in the body with the majority of cancers of the breast, colon and prostate also being adenocarcinomas. Adenocarcinomas also occur in the lung and other tissues. Treatment of a wide variety of cancers in addition to adenocarcinomas is anticipated by the present invention.

A bifunctional hormone exhibiting an alpha-MSH activity and a natriuretic peptide activity is described. The bifunctional hormone comprises for example a first domain having alpha-MSH related hormonal activity covalently linked to a second domain having natriuretic peptide related hormonal activity. The bifunctional hormone of the present invention is useful for example for the prevention and / or treatment of renal related diseases or conditions, such as acute renal failure (ARF) or acute kidney injury (AKI).

The invention provides a human N-terminal pro-B-type natriuretic peptide (NT-proBNP) immunoassay kit, mainly comprising 1) a human NT-proBNP calibration material; 2) a vector coated with human NT-proBNP polyclonal antibodies; 3) an enzyme-labeling human NT-proBNP monoclonal antibody; and 4) an enzymatic chemical luminous substrate. The invention further provides a preparation method of the kit. On the basis of the kit of the invention, the enzyme-labeling human NT-proBNP monoclonal antibody, the human NT-proBNP polyclonal antibodies coated on the vector and human NT-proBNP antigens form a 'double-antibody sandwich' structure, thus effectively utilizing a chemiluminescence technical principle and guaranteeing detection sensitivity. In addition, the kit can be applied to an open chemiluminescence measuring instrument; and the kit has low use cost and easier popularization and application.

The invention disclosed herein relates to oxidized forms of brain natriuretic peptide (BNP), particularly human BNP (hBNP). The disclosed invention relates to oxidized forms of B-type natriuretic peptide (BNP), which is useful as a marker for cardiovascular disease

The present invention discloses proteinaceous compounds that comprise at least a biologically active portion of a taipan natriuretic peptide (TNP) or a variant or derivative thereof. The invention also relates to the use of these compounds in methods for stimulating vasodilation, natriuresis, diuresis, renin-suppression, bactericidal activity, weight-loss or bone growth in a mammalian host. In specific embodiments, the compounds are useful in the treatment of congestive heart failure.

The invention belongs to the field of medicine, particularly relates to a diagnostic technique of heart failure, and specifically relates to a B cell epitope peptide segment of amino-terminal pro-brain natriuretic peptide. An amino acid sequence is shown in SEQ ID NO:4 or SEQ ID NO:5. The prepared specific antibody can be used as a diagnostic reagent of heart failure. The amino-terminal pro-brain natriuretic peptide prepared by the invention is high-purity monomer recombinant protein of the amino-terminal pro-brain natriuretic peptide. The protein can be used for immunogen and screening collagen prepared from an antibody, and can be simultaneously used as a calibrator when the amino-terminal pro-brain natriuretic peptide is built to carry out quantitative detection. A monoclonal antibody prepared by immune mice at the B cell epitope peptide segment of the amino-terminal pro-brain natriuretic peptide has the advantages of high purity (SDS-PAGE detection purity greater than 96%), high valence (the valence of ELISA up to 1:512000), good specificity, mass preparation, and the like.

The present invention relates to a method and means for diagnosing or risk stratification of co-morbidities, particularly cardiovascular complications in diabetes patients. The invention particularly relates to a method for diagnosing whether a diabetes patient is suffering from a cardiovascular complication or is at risk of suffering from a cardiovascular complication, said method comprising the steps of (a) measuring, preferably in vitro, the level(s) of at least one cardiac hormone or a variant thereof in a sample from the patient, and (b) diagnosing the cardiovascular complication or the risk of suffering from cardiovascular complication by comparing the measured level(s) to known level(s) associated with the cardiovascular complication or risk. The present invention also relates to combining the measurement of markers comprising cardiac hormones, natriuretic peptides, inflammation-associated markers, angiogenesis markers, and markers for platelet activation. Preferred markers are brain natriuretic peptides (particularly NT-proBNP), PIGF, and sCD40L.

The invention discloses an optical biosensor for detecting brain natriuretic peptide (BNP) and a preparation method of a reagent thereof, relating to the biosensing technology. A sensor reaction zone is a capillary channel filled with magnetic nano probe solution, the inner surface of the channel is assembled with a layer of hydrophilic nano material, the upper surface of the channel is an euphotic insulating encapsulation layer with an injection hole, the side surface of the channel is encapsulated by plastics, the two ends thereof encapsulated with plastics are respectively provided with a controllable electromagnet. The preparation method of the reagent is as follows: preparing magnetic nano probes, fully reacting the magnetic nano probes, a brain natriuretic peptide (BNP) sample to bedetected and specificity BNP antigen marked by a marker under the united action of the electromagnet and the capillary channel, forming a compound of magnetic nano probes, BNP antigen to be detected and marked antibody, and adding substrate for catalytic luminescence or exciting luminescent quantum dots for luminescence. By the sensor detection system, the BNP concentration can be rapidly detected. The sensor in the invention can rapidly detect the BNP concentration in a sample, and has the characteristics of high specificity, high sensitivity, a great quantity of saved biological reagent andthe like.

The invention relates to a cardiac muscle control material, a preparation method therefor, a detection kit and a detection device for cardiac muscle. The cardiac muscle control material comprises quality control component and protection component, the quality control component comprises at least one of B-type natriuretic peptide, D-dimer, NT-proBNP, cardiac troponin I, myoglobin, creatine kinase isozyme and cardioid fatty acid binding protein and heart fatty acid binding protein. The protective component comprises 5 mM to 100 mM of a buffer agent, 0.5 % to 5% by weight of an excipient, 0.05 mMto 5 mM of an antioxidant, 0.05 mM to 15 mM of a protease inhibitor, 0.5% to 10% by weight of a stabilizer and 0.01% to 2% by weight of a surfactant. The cardiac muscle control material disclosed bythe invention is good in stability.

The present invention relates to materials and procedures for evaluating the prognosis of patients suffering from acute coronary syndromes. In particular, the level of BNP, or a marker related to BNP, in a patient sample, alone or in combination with one or more other prognostic markers, provides prognostic information useful for predicting near-term morbidity and / or mortality across the entire spectrum of acute coronary syndromes, including unstable angina, non-ST-elevation non-Q wave myocardial infarction, ST-elevation non-Q wave MI, and transmural (Q-wave) MI.

The invention discloses a competitive latex-particle-enhanced immunoturbidimetric assay kit for BNP (B-type natriuretic peptide) and a preparation method thereof, and solves the problems of high difficulty in BNP assay, long time for assay and the like in the current sandwich method. The kit disclosed by the invention is composed of latex particles and reaction buffer, and is characterized in that the latex particles are coated with the following artificially-synthesized amino acid sequences: FGRKMDR-X, and X consists of 2 to 4 Ks. The invention further provides a preparation method of the kit.. The kit disclosed by the invention has the advantages of high accuracy, short time for assay, high reliability, etc.

An isolated chimeric peptide consisting of one or two added peptides and an object peptide wherein the added peptide is bonded to the N-terminus, the C-terminus or both of the object peptide, wherein if the added peptides are bound to both terminals, the two added peptides may be the same or different; and physiological activity of the object peptide is still retained, wherein the object peptide is a natural physiologically active peptide selected from the group consisting of an atrial natriuretic peptide, a brain natriuretic peptide, a C-type natriuretic peptide, motilin, a glucagon-like peptide 1, parathyroid hormone, and calcitonin, or a derivative of any thereof, wherein the derivative has one or more amino acid(s) deleted from the amino acid sequence of a natural physiologically active peptide and has the desired physiological activity.